436 results about "Neuropathic pain" patented technology

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The present invention relates to novel compounds that inhibit Nav1.8 sodium channels, methods of making, and methods of using thereof. The present disclosure is further directed to administering the disclosed compounds as therapeutic solutions for acute, chronic, and neuropathic pain to a subject in need thereof.

Obstructive sleep apnea from blockage of the upper airway can result in significant health issues. Described herein is an intelligent personalized closed loop neuromodulation system and methods to prevent backwards movement of the genioglossus muscle through stimulation of certain branches of the hypoglossal nerve and muscle motor points, by using muscle feedback from electromyogram sensors to provide optimal stimulus. Alternative embodiments to treat neuropathic pain and urinary dysfunction are enclosed.

In the herpes zoster neuralgia chronic detection and AI identification model training method and system, information of a detector is collected, and the information of the detector comprises age, gender and herpes zoster definite diagnosis time; collecting detection information of a detector, wherein the detection information comprises a ratio of IL18 to IL18BP; pain information of the detected person is collected; the pain information of the detector comprises pain intensity and attack frequency; the pain information of the detected person is marked, marked information is obtained, and the marked information comprises acute pain, chronic pain and the risk degree of converting the acute pain into the chronic pain; performing AI training according to the detector information, the detection information and the annotation information, and obtaining a herpes zoster neuropathic pain AI feature data set after the AI training; the herpes zoster neuralgia AI feature data set is used for detecting the possibility that the herpes zoster neuralgia of the testee is converted from acute pain to chronic pain in combination with AI software. And diagnosis and treatment basis information from a brand new perspective is provided for the post-herpes zoster neuralgia.

The invention belongs to the field of massage control, and relates to a hand massager which comprises a base, an upper cover and a cavity arranged between the base and the upper cover, the cavity is defined by a first lining piece and a second lining piece and is provided with a plurality of air bags used for different areas of a hand, and the air bags comprise a finger air bag, a hand back air bag, an upper wrist air bag, a lower wrist air bag and a palm air bag; the cavity extends to the middle section of the arm of a user, and two or more EMS electrotherapy sheets are arranged in the cavity and connected to the control panel; a dip angle alpha is arranged at the bottom of the cavity, so that the palm and the wrist of a user are kept in a natural fit posture, the dip angle structure is fixed or suspended, and an elastic element is arranged below the suspended dip angle structure; and a lithium battery is also arranged in the hand massager. The problems that a traditional massager only limits physical pressing, is insufficient in coverage area and poor in comfort are solved, the massage depth and the treatment effect are remarkably improved, and the massager is suitable for relieving hand fatigue and neuropathic pain and assisting in rehabilitation treatment.

The invention relates to the field of medicines. Specifically, the invention relates to a voltage-gated calcium channel alpha2delta subunit ligand containing a polycyclic gamma-aminobutyric acid structure as shown in a general formula I, a preparation method of the voltage-gated calcium channel alpha2delta subunit ligand and application of the voltage-gated calcium channel alpha2delta subunit ligand to treatment of chronic neuropathic pain, epilepsy and anxiety. # imgabs0 #

The present invention provides a tetrazole compound, a pharmaceutical composition thereof and a use thereof. The compound of the present invention has a brand-new structure, a low clearance rate, high plasma exposure, good oral bioavailability, and good pharmacokinetic properties, and is conducive to drug development. The compound of the present invention or a pharmaceutically acceptable salt thereof can be used for preventing and / or treating pain, including neuropathic pain, etc.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The invention discloses radio frequency treatment equipment for neuropathic pain, and relates to the technical field of medical radio frequency equipment. The device comprises a developing scanner, an electric bed frame is arranged at the bottom of the developing scanner, an electric bed plate is installed at the top of the electric bed frame in a driving mode, a transposition arc frame is installed in the developing scanner in a driving mode and located at the top of the electric bed plate, and an adjusting outer ring is fixedly installed at the top of the transposition arc frame; an adjusting inner ring is installed in the adjusting outer ring in a driving mode, and transposition drivers are fixedly installed on the inner walls of the two sides of the adjusting inner ring. By arranging the storage assembly, the storage assembly can be matched with the automatic puncture equipment to put down an old puncture tube needle and reinstall the automatic puncture equipment on the transposition arc frame for next round of puncture and treatment, semi-automatic replacement of the puncture tube needle is achieved, medical staff do not need to make contact with the puncture tube needle and a puncture sleeve in the whole process, and the puncture efficiency is improved. The replacement process is simplified, and the interval between two rounds of radio frequency treatment is shortened.

The present invention relates to a voltage-gated sodium channel Nav1.8 selective inhibitor and the use thereof in the preparation of a related drug. The drug is used for treating diseases responsive to the inhibition of voltage-gated sodium channel NaV1.8, such as chronic pain, enterodynia, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, post-operative pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough or arrhythmia. Specifically, the present invention relates to a compound as shown in formula (X), and an isomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof.

The disclosure relates to compounds of formula I, wherein X, and R1-R4, n, and m have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I exhibit GPR 183 antagonistic activity and are thus useful in the treatment or prevention of disorder, condition, or disease where GRP183 antagonist is indicated to be useful, such as e.g. chronic pain e.g osteoarthritis, chronic low back pain, neuropathic pain and immune system diseases e.g inflammatory bowel diseases e.g. Colitis and Chron's diseases, multiple sclerosis, rheumatoid arthritis, inflammatory pulmonary diseases e.g. asthma and psoriasis.

The invention belongs to the technical field of medicines, and provides a compound containing an oxopyridine and alicyclic ring or alicyclic ring structure as shown in a formula I. R2, R3, X1, X2, X3, X4, X5, Y1, Y2, A, o and n are defined in the specification. The compound with the novel structure provided by the invention has excellent CGRP antagonistic activity, and has potential treatment on various diseases mediated and regulated by CGRP, especially migraine or neuropathic pain.

The present invention is directed to novel compounds that inhibit Nav1.8 sodium channels, methods of making, and methods of using thereof. The present disclosure is further directed to administering the disclosed compounds as therapeutic solutions for chronic pain, primary pain, idiopathic pain, gastrointestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer-related pain, idiopathic pain, postoperative pain, visceral pain, multiple sclerosis, Summer-Marr-Tuff syndrome, incontinence, pathological cough, or arrhythmia to a subject in need thereof.

The present invention relates to an angiotensin II receptor antagonist and a use thereof in the treatment of peripherally-induced neuropathic pain. In particular, the present invention provides a compound of formula (IV) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, and a use thereof in the treatment of peripherally-induced neuropathic pain.

Described herein is a composition that includes an N-methyl-D-aspartate receptor (NMDAR) antagonist and a TAS2R receptor response mediating agent for treating neuropathic pain and depression. Methods for treating chronic pain with the described composition are also described.

The present disclosure provides methods of treating multiple sclerosis associated spasticity or neurological pain in a patient with renal impairment by administering cannabinoids oromucosal spray.

The invention provides a nano-drug carrier and a drug release system, the nano-drug carrier comprises a drug loading core and a responsive shell arranged outside the drug loading core, and the drug loading core is loaded with a nano-drug; the surface of the responsive shell is modified with a targeting ligand, and the targeting ligand can specifically target pain-related cells or tissues. According to the nano-drug carrier and the drug release system provided by the invention, precise long-acting treatment of chronic pain is realized through combination of an environment-responsive carrier and an active targeting technology. The technology can significantly improve local accumulation of the medicine and reduce systemic toxicity, and is suitable for management of intractable pains such as neuropathic pains and osteoarthritis.

The invention relates to dexcamphanol or fenchol ester derivatives of 2-hydroxynicotinic acid and pharmaceutical application of the dexcamphanol or fenchol ester derivatives, and belongs to the technical field of biological medicine. The structural general formula of the derivative disclosed by the invention is # imgabs0 #, wherein R1 is selected from-H,-Cl, alkyl with 1 to 8 carbon atoms,-CF3,-CF2H,-CN,-SCH3,-OH,-CHO,-CH2OH,-CH2NH2,-COOH, halogenated phenyl or-NR4R5; r4 and R5 are independently selected from-H or-CH3; r2 is selected from-H, alkyl with 1-6 carbon atoms, and acyl or carbamoyl with 2-7 carbon atoms; r3 is selected from # imgabs1; # X is selected from-CH = or-N =. The derivative disclosed by the invention has a good inflammation inhibition effect; and under the condition of high concentration, the compound has lower cytotoxicity and is safer. The compound can be used for preparing medicines for treating inflammation and inflammation-related diseases such as cerebral apoplexy, neuropathic pain, depression and senile dementia.

Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, (I) can inhibit HCN1 / HCN2 and are expected to have utility as therapeutic agents, for example, for treating inhibiting, or ameliorating pain, such as, inflammatory and / or neuropathic pain, central nervous system (CNS) and psychiatric disorders, mood disorders, and tinnitus. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of, pain, such as, inflammatory and / or neuropathic pain, central nervous system (CNS) and psychiatric disorders, mood disorders, and tinnitus, and for preparing pharmaceuticals for this purpose.

The utility model relates to an operation threading hook for neuropathic pain. The operation threading hook comprises a handle, a threading needle and a curve hook, the threading needle is arranged on the front section of the handle, the curve hook is assembled at the end, away from the handle, of the threading needle, and threading channels communicated with one another are formed in the handle, the threading needle and the threading hook. According to the surgical threading hook for neuropathic pain, the handle is held, the extrusion ring is rotated by the thumb to drive the pushing roller to rotate, and the rotating shaft located in the pushing roller rotates along with the pushing roller, that is, when the pushing roller rotates clockwise, a suture line can be pushed to move towards a threading needle, and otherwise, the suture line moves towards the tail end of the handle; when the suture pushing device is used, a user can accurately control the pushing direction and speed of the suture by rotating the extrusion ring, accurate operation of the suture is achieved, the structure is easy to operate, pushing of the suture can be controlled only through one finger, and operation convenience and flexibility are improved.

The invention provides application of PRP-Exos in preparation of a medicine for treating neuropathic pain, and relates to the technical field of clinical medicine. According to the invention, the treatment effect of PRP-Exos on neuropathic pain by inhibiting a TLR4 / NF-kappa B signal channel is clarified, a new thought is provided for clinical transformation, meanwhile, an intrathecal injection delivery mode is adopted, the limitation of low bioavailability of peripheral administration is overcome, meanwhile, the treatment effect is comprehensively verified through a behavioral-histological-molecular biological multi-modal evaluation system, and the application prospect is wide. The potential of the PRP-Exos in relieving the neuropathic pain is proved.

To provide an antibody that can adjust FAM19A5 activity by specifically binding to FAM19A5.SOLUTION: In certain embodiments, an antibody which specifically binds to FAM19A5 is de-immunized in order to reduce immunogenicity in a human subject. In some embodiments, an anti FAM19A5 antibody is capable of adjusting FAM19A5 activity by using the antibody, and can suppress, decrease, reduce or invert excessive proliferation of reactive gliosis and / or reactive astrocytes for example. Also provided is a method for treating disorders such as central nervous system injury, degenerative brain disorder, neuropathic pain and cancer by administering an antibody which specifically binds to human FAM19A5.SELECTED DRAWING: Figure 1A

Disclosed herein are anti-RGMa antibodies and methods of using these antibodies to treat spinal cord injury, including promoting axonal regeneration, functional recovery, or both and to treat pain, including neuropathic pain arising from spinal cord injury.

The present invention provides the use of phenylquinolinone and flavonoid derivatives for neuropathic pain, and the phenylquinolinone and flavonoid derivatives include pharmaceutically acceptable salts thereof. The compound of the present invention is a histamine H3 receptor antagonist, which has a different mechanism of action from existing drugs and can be used in the preparation of drugs for treating neuropathic pain diseases. The effect of the compound of the present invention in treating neuropathic pain is better than amitriptyline, gabapentin, pregabalin and carbamazepine, indicating that the compound of the present invention has a better therapeutic effect, has the characteristics of small dosage, good efficacy, high bioavailability and safety, and compared with opioid drugs, the compound of the present invention is not addictive and is a very effective drug for treating neuropathic pain diseases. Therefore, the clinical application prospects are huge. The general structural formula is as follows: